BDTX Logo

Black Diamond Therapeutics, Inc. (BDTX) 

NASDAQ
Market Cap
$136.09M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
459 of 775
Rank in Industry
240 of 432

Largest Insider Buys in Sector

BDTX Stock Price History Chart

BDTX Stock Performance

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance …

Insider Activity of Black Diamond Therapeutics, Inc.

Over the last 12 months, insiders at Black Diamond Therapeutics, Inc. have bought $0 and sold $1.4M worth of Black Diamond Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Black Diamond Therapeutics, Inc. have bought $60M and sold $10.24M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 400,000 shares for transaction amount of $934,080 was made by BIOTECH GROWTH N V (10 percent owner) on 2023‑10‑17.

List of Insider Buy and Sell Transactions, Black Diamond Therapeutics, Inc.

2024-08-28Sale10 percent owner
221,600
0.3894%
$6.32$1.4M-42.54%
2023-10-17Purchase10 percent owner
400,000
0.7707%
$2.34$934,080+99.57%
2023-07-05Purchasedirector
1M
2.8199%
$5.00$5M-26.34%
2023-07-05Purchasedirector
935,850
2.639%
$5.00$4.68M-26.34%
2023-06-30Purchase10 percent owner
1M
2.7138%
$5.00$5M-28.71%
2023-06-27SaleSEE REMARKS
25,000
0.0743%
$6.70$167,500-41.59%
2023-06-27Purchase10 percent owner
1.74M
4.2378%
$5.49$9.56M-41.59%
2022-12-22PurchaseSEE REMARKS
36,363
0.0972%
$1.28$46,596+73.11%
2022-12-21PurchaseSEE REMARKS
20,000
0.0546%
$1.29$25,770+74.62%
2022-10-31Purchasedirector
99,801
0.268%
$2.25$224,912-6.28%
2022-10-28Purchasedirector
172,974
0.4696%
$2.18$376,962-1.81%
2022-10-27Purchasedirector
191,678
0.5124%
$1.87$359,224+12.69%
2022-10-21Purchasedirector
87,850
0.2313%
$1.51$132,750+37.97%
2022-10-20Purchasedirector
53,734
0.144%
$1.42$76,345+48.97%
2022-10-19Purchasedirector
77,689
0.2096%
$1.32$102,775+61.48%
2022-06-29PurchaseSEE REMARKS
25,000
0.0681%
$2.44$61,018-16.60%
2022-04-27Purchase
150,000
0.4047%
$2.66$399,480-22.79%
2022-04-18Purchase
150,000
0.4099%
$3.29$493,935-35.24%
2022-04-12Purchase
150,000
0.4078%
$3.42$513,600-37.46%
2021-05-12SaleSee Remarks
4,078
0.0111%
$27.42$111,805-72.50%

Insider Historical Profitability

<0.0001%
Versant Venture Capital VI, L.P.10 percent owner
3726341
6.5854%
$2.41128<0.0001%
BIOTECH GROWTH N V10 percent owner
8517839
15.0531%
$2.4190+10.34%
Behbahani Alidirector
4448757
7.8621%
$2.4120<0.0001%
BB BIOTECH AG
4438402
7.8438%
$2.4130<0.0001%
RA CAPITAL MANAGEMENT, L.P.director
3213828
5.6796%
$2.4110<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Bellevue Group$43.19M15.148.52M-0.21%-$91,260.000.66
T Rowe Price Investment Management Inc$34.1M11.966.73M+71.22%+$14.18M0.02
Nea Management Company Llc$22.56M7.914.45M0%+$00.11
RA Capital Management, L.P.$17.88M6.273.53M0%+$00.02
The Vanguard Group$9.66M3.391.91M-2.15%-$211,890.51<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.